Please login to the form below

Not currently logged in
Email:
Password:

Amgen sues Sanofi and Regeneron over eczema drug

Alleges patent infringement and seeks financial reparations

Amgen

Amgen's subsidiary Immunex has filed a lawsuit against Sanofi and Regeneron alleging patent infringement with the duo's recently-approved eczema drug Dupixent.

Dupixent (dupilumab) - an interleukin-4 (IL-4) and IL-13 inhibitor - was approved for eczema (atopic dermatitis) patients who do not respond to or should not use topical prescription therapies last month. It is one of the hottest prospects in Sanofi and Regeneron's pipeline with analysts predicting peak sales of up to $3bn.

Immunex claims that it will suffer damages as a result of Sanofi and Regeneron's ‘infringing activities’ with Dupixent, but its lawsuit was filed in response to a ‘keep-away’ suit - filed by Sanofi and Regeneron last month - seeking an early judgment that Dupixent does not trespass on Immunex' patent estate.

"Sanofi and Regeneron wish to eliminate any potential obstacle Amgen might seek to raise against the planned US commercialisation of Dupixent," said the pair in that earlier complaint.

This is the second major legal spat between the parties, which are already locked in litigation over their cholesterol-lowering PCSK9 inhibitor drug. In February a US appeals court suspended an injunction barring the sale of Sanofi and Regeneron's PCSK9 inhibitor Praluent (alirocumab), after Amgen won a ruling that Praluent infringed two patents covering its own PCSK9 inhibitor Repatha (evolocumab).

On this occasion Amgen does not have a direct competitor to Dupixent in the pipeline or on the market, so it is not seeking an injunction on sales of Dupixent but would like financial recompense for its intellectual property. The company had previously explored developing asthma drugs based on IL-4 receptor antagonists.

Specifically Immunex says it has a US patent (No. 8,679,487) covering the use of antibodies targeting the IL-4 receptor and a specific molecule - 12B5 - which it claims Regeneron used in its own discovery efforts that resulted in the identification of dupilumab.

Article by
Phil Taylor

21st April 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics